PortfoliosLab logoPortfoliosLab logo
PHAR vs. TRMD
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PHAR vs. TRMD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pharming Group NV (PHAR) and TORM plc (TRMD). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PHAR achieves a -22.07% return, which is significantly lower than TRMD's 54.81% return.


PHAR

1D
-0.65%
1M
7.54%
6M
-26.68%
YTD
-22.07%
1Y
37.70%
3Y*
4.12%
5Y*
4.03%
10Y*

TRMD

1D
-2.10%
1M
-5.07%
6M
34.96%
YTD
54.81%
1Y
74.18%
3Y*
23.44%
5Y*
45.06%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

PHAR vs. TRMD - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
PHAR
Pharming Group NV
-22.07%75.56%-11.94%3.63%23.38%-41.16%-20.82%
TRMD
TORM plc
54.81%11.21%-23.37%31.64%297.66%12.91%0.57%

Correlation

The correlation between PHAR and TRMD is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.09

Correlation (3Y)
Calculated over the trailing 3-year period

0.05

Correlation (5Y)
Calculated over the trailing 5-year period

0.06

Correlation (All Time)
Calculated using the full available price history since Dec 23, 2020

0.06

Fundamentals

Market Cap

PHAR:

$972.51M

TRMD:

$2.95B

EPS

PHAR:

$74.81

TRMD:

$3.40

PE Ratio

PHAR:

0.18

TRMD:

8.49

PS Ratio

PHAR:

0.01

TRMD:

2.07

PB Ratio

PHAR:

3.59

TRMD:

1.31

Total Revenue (TTM)

PHAR:

$106.76B

TRMD:

$1.41B

Gross Profit (TTM)

PHAR:

$85.64B

TRMD:

$575.03M

EBITDA (TTM)

PHAR:

$6.24B

TRMD:

$639.99M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Pharming Group NV

TORM plc

Return for Risk

PHAR vs. TRMD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PHAR
PHAR Risk / Return Rank: 6464
Overall Rank
PHAR Sharpe Ratio Rank: 6464
Sharpe Ratio Rank
PHAR Sortino Ratio Rank: 6363
Sortino Ratio Rank
PHAR Omega Ratio Rank: 6565
Omega Ratio Rank
PHAR Calmar Ratio Rank: 6464
Calmar Ratio Rank
PHAR Martin Ratio Rank: 6363
Martin Ratio Rank

TRMD
TRMD Risk / Return Rank: 8888
Overall Rank
TRMD Sharpe Ratio Rank: 9191
Sharpe Ratio Rank
TRMD Sortino Ratio Rank: 8888
Sortino Ratio Rank
TRMD Omega Ratio Rank: 8484
Omega Ratio Rank
TRMD Calmar Ratio Rank: 8787
Calmar Ratio Rank
TRMD Martin Ratio Rank: 8888
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PHAR vs. TRMD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Pharming Group NV (PHAR) and TORM plc (TRMD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PHARTRMDDifference
Sharpe ratioReturn per unit of total volatility

-1.40

Sortino ratioReturn per unit of downside risk

-1.43

Omega ratioGain probability vs. loss probability

1.16

1.30

-0.14

Calmar ratioReturn relative to maximum drawdown

0.87

3.17

-2.30

Martin ratioReturn relative to average drawdown

1.82

8.27

-6.46

PHAR vs. TRMD - Sharpe Ratio Comparison

The current PHAR Sharpe Ratio is 0.55, which is lower than the TRMD Sharpe Ratio of 1.95. The chart below compares the historical Sharpe Ratios of PHAR and TRMD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PHAR vs. TRMD - Drawdown Comparison

The maximum PHAR drawdown since its inception was -65.58%, which is greater than TRMD's maximum drawdown of -60.59%. Use the drawdown chart below to compare losses from any high point for PHAR and TRMD.


Loading charts...

Drawdown Indicators


PHARTRMDDifference

Max Drawdown

Largest peak-to-trough decline

-65.58%

-60.59%

-4.99%

Max Drawdown (1Y)

Largest decline over 1 year

-43.34%

-23.53%

-19.81%

Max Drawdown (3Y)

Largest decline over 3 years

-57.32%

-60.59%

+3.27%

Max Drawdown (5Y)

Largest decline over 5 years

-57.32%

-60.59%

+3.27%

Current Drawdown

Current decline from peak

-34.99%

-15.31%

-19.68%

Average Drawdown

Average peak-to-trough decline

-41.75%

-22.49%

-19.26%

Ulcer Index

Depth and duration of drawdowns from previous peaks

20.81%

9.01%

+11.80%

Volatility

PHAR vs. TRMD - Volatility Comparison

The current volatility for Pharming Group NV (PHAR) is 8.89%, while TORM plc (TRMD) has a volatility of 13.20%. This indicates that PHAR experiences smaller price fluctuations and is considered to be less risky than TRMD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PHARTRMDDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.89%

13.20%

-4.31%

Volatility (6M)

Calculated over the trailing 6-month period

48.27%

29.05%

+19.22%

Volatility (1Y)

Calculated over the trailing 1-year period

68.97%

38.28%

+30.69%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

70.12%

46.29%

+23.83%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

67.93%

59.69%

+8.24%

Dividends

PHAR vs. TRMD - Dividend Comparison

PHAR has not paid dividends to shareholders, while TRMD's dividend yield for the trailing twelve months is around 8.39%.


PositionTTM202520242023202220212020
PHAR
Pharming Group NV
0.00%0.00%0.00%0.00%0.00%0.00%0.00%
TRMD
TORM plc
8.39%10.32%30.13%23.05%6.99%0.00%14.89%

Financials

PHAR vs. TRMD - Financials Comparison

This section allows you to compare key financial metrics between Pharming Group NV and TORM plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B100.00BJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
72.71M
395.84M
(PHAR) Total Revenue
(TRMD) Total Revenue
Values in USD except per share items

PHAR vs. TRMD - Profitability Comparison

The chart below illustrates the profitability comparison between Pharming Group NV and TORM plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

40.0%50.0%60.0%70.0%80.0%90.0%100.0%JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
90.8%
39.9%
Portfolio components
PHAR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Pharming Group NV reported a gross profit of 66.04M and revenue of 72.71M. Therefore, the gross margin over that period was 90.8%.

TRMD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, TORM plc reported a gross profit of 157.74M and revenue of 395.84M. Therefore, the gross margin over that period was 39.9%.

PHAR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Pharming Group NV reported an operating income of 2.52M and revenue of 72.71M, resulting in an operating margin of 3.5%.

TRMD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, TORM plc reported an operating income of 135.10M and revenue of 395.84M, resulting in an operating margin of 34.1%.

PHAR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Pharming Group NV reported a net income of -5.23M and revenue of 72.71M, resulting in a net margin of -7.2%.

TRMD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, TORM plc reported a net income of 120.52M and revenue of 395.84M, resulting in a net margin of 30.5%.


Frequently Asked Questions


PHAR and TRMD have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

TRMD has higher volatility (13.20%) compared to PHAR (8.89%). In terms of maximum drawdown, PHAR dropped -65.58% vs TRMD's -60.59%.

TRMD currently has the higher Sharpe Ratio (1.95 vs 0.55), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PHAR and TRMD

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer